MedPath

A study to assess the effects of Apremilast and Methotrexate in the treatment of patients with psoriasis

Not Applicable
Conditions
Health Condition 1: L400- Psoriasis vulgaris
Registration Number
CTRI/2019/01/017362
Lead Sponsor
RATHIPRIYADHARSHINI R
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Those With chronic plaque psoriasis involving >10%BSA

Those who sign the written consent form prior to participation in the study

Exclusion Criteria

pregnancy

lactation

abnormalities in LFT,RFT,CBC

hypertension and diabetes

active tuberculosis/ HIV infection

Hypersensitivity to the drugs

Those on immunosuppresive medications

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath